RE:RE:MEDXF gets CRLNone of what you said is true. The ceo had mentioned many times he felt extremely confident approval would happen and that they would get expanded indication for pediatric. This was somewhat based on their discussions with the fda. Go back and listen to the calls. They missed their numbers last quarter and if you look at the comparison to last quarter, they decreased which was a big question for analysts on the earnings call. They spent a lot of money for this drug and it's possible the delay and eventual approval could take 1-2+ years to work out. Not good. Ken had stated many times this drug was going to be a defining moment for the company going forward. This is not good. Hopefully for the company the CRL is not too harsh and that revenues reaccelerate next quarter. Kenn needs to come out and say something to shareholders